摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(3-benzoxy-5-methoxyphenyl)-6,7-methylenedioxy-1H-quinolin-4-one | 1355235-79-8

中文名称
——
中文别名
——
英文名称
2-(3-benzoxy-5-methoxyphenyl)-6,7-methylenedioxy-1H-quinolin-4-one
英文别名
2-(3-benzyloxy-5-methoxyphenyl)-6,7-methylenedioxyquinolin-4(1H)-one;2-(3-Benzyloxy-5-methoxyphenyl)-6,7-methylenedioxyquinolin-4-one;6-(3-methoxy-5-phenylmethoxyphenyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one
2-(3-benzoxy-5-methoxyphenyl)-6,7-methylenedioxy-1H-quinolin-4-one化学式
CAS
1355235-79-8
化学式
C24H19NO5
mdl
——
分子量
401.419
InChiKey
IAXPAPVPOLMYIN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.4
  • 重原子数:
    30
  • 可旋转键数:
    5
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    66
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-(3-benzoxy-5-methoxyphenyl)-6,7-methylenedioxy-1H-quinolin-4-one 在 palladium 10% on activated carbon 氢气 、 sodium hydride 作用下, 以 四氢呋喃甲醇 、 mineral oil 为溶剂, 反应 24.17h, 生成 dibenzyl 2-(3-([bis-[(benzyl)oxy]]phosphoryl)oxy-5-methoxyphenyl)-6,7-methylenedioxyquinolin-4-ylphosphate
    参考文献:
    名称:
    SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES
    摘要:
    根据以下公式披露了一种化合物:或其药学上可接受的盐、前药、溶剂合物或代谢物,其中R为氢、P(═O)(OH)2、P(═O)(O(C1-C18)烷基(C6-C20)芳基)2、P(═O)(OH)(OM)、P(═O)(OM)2、P═O(O2M)、S(═O)(OH)2、S(═O)(O(C1-C18)烷基(C6-C20)芳基)2、S(═O)(OH)(OM)、S(═O)(OM)2;M为一价或二价金属离子,或烷基铵离子;W为(C6-C20)芳基、(C6-C20)杂芳基、(C1-C18)烷基(C6-C20)芳基、(C1-C18)烷基(C6-C20)杂芳基、羟基(C6-C20)芳基、羟基(C6-C20)杂芳基、(C1-C18)烷氧基(C6-C20)芳基、(C1-C18)烷氧基(C6-C20)杂芳基、(C1-C18)烷二氧基(C6-C20)芳基、(C1-C18)烷二氧基(C6-C20)杂芳基、卤代(C6-C20)芳基、卤代(C6-C20)杂芳基、(C1-C18)烷基氨基(C6-C20)芳基、(C1-C18)烷基氨基(C6-C20)杂芳基、(C1-C18)环烷基氨基(C6-C20)芳基,或(C1-C18)环烷基氨基(C6-C20)杂芳基,以及它们的OR8取代基;R5为(C1-C18)烷氧基、氢、羟基、O—(C1-C18)烷基(C6-C20)芳基、卤素或OR8,或R5和R6为(C1-C18)二氧基,前提是R7为氢;R6为羟基、O—(C1-C18)烷基(C6-C20)芳基、卤素或ORR、(C1-C18)烷氧基、(C1-C18)烷基氨基,或(C1-C18)环烷基氨基,或R6和R7为(C1-C18)二氧基,前提是R5为氢;R7为氢、卤素或OR8、羟基,或O—(C1-C18)烷基(C6-C20)芳基;R8为P(═O)(OH)2、P(═O)(O(C1-C18)烷基(C6-C20)芳基)2、P(═O)(OH)(OM)、或P(═O)(OM)2、P═O(O2M)。
    公开号:
    US20120015908A1
  • 作为产物:
    描述:
    参考文献:
    名称:
    Mechanistic Studies on Regioselective Dephosphorylation of Phosphate Prodrugs during a Facile Synthesis of Antitumor Phosphorylated 2-Phenyl-6,7-methylenedioxy-1H-quinolin-4-one
    摘要:
    2-(3-羟基-5-甲氧基苯基)-6,7-亚甲二氧基-1H-喹啉-4-酮(1)的磷酸化得到二磷酸2。我们发现,在温和条件下用甲醇处理后,2可以很容易地发生磷酸化。高度区域选择性去磷酸化得到单磷酸3,其中苯环上保留有磷酸基团。假设去磷酸化过程的细节,然后通过 LC-MS 和 HPLC 分析进行探讨。此外,作为初步研究,水溶性单磷酸盐前药4针对MCF-7异种移植裸鼠模型进行了抗肿瘤活性测试。
    DOI:
    10.3390/molecules18078028
点击查看最新优质反应信息

文献信息

  • [EN] SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES<br/>[FR] SYNTHÈSE ET ACTIVITÉ ANTICANCÉREUSE DE DÉRIVÉS D'ARYL- ET D'HÉTÉROARYL-QUINOLÉINE
    申请人:EFFICIENT PHARMA MAN CORP
    公开号:WO2012009519A1
    公开(公告)日:2012-01-19
    A class of compounds that are derivatives and analogues of aryl and heteroaryl-quinolin is disclosed. Also disclosed are synthesis and use of the aryl and heteroaryl -quinolin derivatives and analogues for anticancer activities.
    本文披露了一类衍生自芳基和杂环芳基喹啉的化合物及其类似物。本文还披露了合成和使用这些芳基和杂环芳基喹啉衍生物和类似物进行抗癌活性的方法。
  • Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead
    作者:Yung-Yi Cheng、Chin-Yu Liu、Meng-Tung Tsai、Hui-Yi Lin、Jai-Sing Yang、Tian-Shung Wu、Sheng-Chu Kuo、Li-Jiau Huang、Kuo-Hsiung Lee
    DOI:10.1016/j.bmcl.2013.06.083
    日期:2013.9
    New 6- (or 6,7-) substituted 2-(hydroxyl substituted phenyl)quinolin-4-one derivatives were synthesized and screened for antiproliferative effects against cancer cell lines. Structure-activity relationship correlations were established and the most promising compound 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidin-1-ylquinolin-4-one (6h) exhibited strong inhibitory activity against various human cancer cell lines, particularly non-small cell lung cancer NCI-H522. Additional studies suggested a mechanism of action resembling that of the antimitotic drug vincristine. The presence of a C-ring OH group in 6h will allow this compound to be converted readily to a water soluble and physicochemically stable hydrophilic prodrug. Compound 6h is proposed as a new anticancer lead compound. (C) 2013 Elsevier Ltd. All rights reserved.
  • US8524740B2
    申请人:——
    公开号:US8524740B2
    公开(公告)日:2013-09-03
  • SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES
    申请人:Kuo Sheng-Chu
    公开号:US20120015908A1
    公开(公告)日:2012-01-19
    A compound of Formula I is disclosed as follows: or a pharmaceutically acceptable salt, prodrug, solvate, or metabolite thereof, wherein R is hydrogen, P(═O)(OH) 2 , P(═O)(O(C 1 -C 18 )alkylene(C 6 -C 20 )aryl) 2 , P(═O)(OH)(OM), P(═O)(OM) 2 , P═O(O 2 M), S(═O)(OH) 2 , S(═O)(O(C 1 -C 18 )alkylene(C 6 -C 20 )aryl) 2 , S(═O)(OH)(OM), S(═O)(OM) 2 ; M is a monovalent or divalent metal ion, or alkylammonium ion; W is (C 6 -C 20 )aryl, (C 6 -C 20 )heteroaryl, (C 1 -C 18 )alkyl(C 6 -C 20 )aryl, (C 1 -C 18 )alkyl(C 6 -C 20 )heteroaryl, hydroxy(C 6 -C 20 )aryl, hydroxy(C 6 -C 20 )heteroaryl, (C 1 -C 18 )alkoxy(C 6 -C 20 )aryl, (C 1 -C 18 )alkoxy(C 6 -C 20 )heteroaryl, (C 1 -C 18 )alkylenedioxy(C 6 -C 20 )aryl, (C 1 -C 18 )alkylenedioxy(C 6 -C 20 )heteroaryl, halo(C 6 -C 20 )aryl, halo(C 6 -C 20 )heteroaryl, (C 1 -C 18 )alkylamino(C 6 -C 20 )aryl, (C 1 -C 18 )alkylamino(C 6 -C 20 )heteroaryl, (C 1 -C 18 )cycloalkylamino(C 6 -C 20 )aryl, or (C 1 -C 18 )cycloalkylamino(C 6 -C 20 )heteroaryl, and their OR 8 substutes; R 5 is (C 1 -C 18 alkoxy, hydrogen, hydroxyl, O—(C 1 -C 18 )alkyl(C 6 -C 20 )aryl, halo or OR 8 , or R 5 and R 6 are (C 1 -C 18 )dioxy provided that R 7 is hydrogen; R 6 is hydroxyl, O—(C 1 -C 18 )alkyl(C 6 -C 20 )aryl, halo or OR R , (C 1 -C 18 )alkoxy, (C 1 -C 18 )alkylamino, or (C 1 -C 18 )cycloalkylamino, or R 6 and R 7 are (C 1 -C 18 )dioxy provided that R 5 is hydrogen; R 7 is hydrogen, halo or OR 8 , hydroxyl, or O—(C 1 -C 18 )alkyl(C 6 -C 20 )aryl; and R 8 is P(═O)(OH) 2 , P(═O)(O(C 1 -C 18 )alkyl(C 6 -C 20 )aryl) 2 , P(═O)(OH)(OM), or P(═O)(OM) 2 , P═O(O 2 M).
    根据以下公式披露了一种化合物:或其药学上可接受的盐、前药、溶剂合物或代谢物,其中R为氢、P(═O)(OH)2、P(═O)(O(C1-C18)烷基(C6-C20)芳基)2、P(═O)(OH)(OM)、P(═O)(OM)2、P═O(O2M)、S(═O)(OH)2、S(═O)(O(C1-C18)烷基(C6-C20)芳基)2、S(═O)(OH)(OM)、S(═O)(OM)2;M为一价或二价金属离子,或烷基铵离子;W为(C6-C20)芳基、(C6-C20)杂芳基、(C1-C18)烷基(C6-C20)芳基、(C1-C18)烷基(C6-C20)杂芳基、羟基(C6-C20)芳基、羟基(C6-C20)杂芳基、(C1-C18)烷氧基(C6-C20)芳基、(C1-C18)烷氧基(C6-C20)杂芳基、(C1-C18)烷二氧基(C6-C20)芳基、(C1-C18)烷二氧基(C6-C20)杂芳基、卤代(C6-C20)芳基、卤代(C6-C20)杂芳基、(C1-C18)烷基氨基(C6-C20)芳基、(C1-C18)烷基氨基(C6-C20)杂芳基、(C1-C18)环烷基氨基(C6-C20)芳基,或(C1-C18)环烷基氨基(C6-C20)杂芳基,以及它们的OR8取代基;R5为(C1-C18)烷氧基、氢、羟基、O—(C1-C18)烷基(C6-C20)芳基、卤素或OR8,或R5和R6为(C1-C18)二氧基,前提是R7为氢;R6为羟基、O—(C1-C18)烷基(C6-C20)芳基、卤素或ORR、(C1-C18)烷氧基、(C1-C18)烷基氨基,或(C1-C18)环烷基氨基,或R6和R7为(C1-C18)二氧基,前提是R5为氢;R7为氢、卤素或OR8、羟基,或O—(C1-C18)烷基(C6-C20)芳基;R8为P(═O)(OH)2、P(═O)(O(C1-C18)烷基(C6-C20)芳基)2、P(═O)(OH)(OM)、或P(═O)(OM)2、P═O(O2M)。
  • Mechanistic Studies on Regioselective Dephosphorylation of Phosphate Prodrugs during a Facile Synthesis of Antitumor Phosphorylated 2-Phenyl-6,7-methylenedioxy-1H-quinolin-4-one
    作者:Yung-Yi Cheng、Chin-Yu Liu、Li-Jiau Huang、Chi-Hung Huang、Kuo-Hsiung Lee、Cheng-Tung Lin、Sheng-Chu Kuo
    DOI:10.3390/molecules18078028
    日期:——
    Phosphorylation of 2-(3-hydroxy-5-methoxyphenyl)-6,7-methylenedioxy-1H-quinolin-4-one (1) afforded diphosphate 2. We found that, upon treatment with methanol under mild conditions, 2 can undergo facile and highly regioselective dephosphorylation to give the monophosphate 3, with a phosphate group remaining on the phenyl ring. The details of the dephosphorylation process were postulated and then probed by LC-MS and HPLC analyses. Furthermore, as a preliminary study, the water soluble monophosphate prodrug 4 was tested for antitumor activity against a MCF-7 xenograft nude mice model.
    2-(3-羟基-5-甲氧基苯基)-6,7-亚甲二氧基-1H-喹啉-4-酮(1)的磷酸化得到二磷酸2。我们发现,在温和条件下用甲醇处理后,2可以很容易地发生磷酸化。高度区域选择性去磷酸化得到单磷酸3,其中苯环上保留有磷酸基团。假设去磷酸化过程的细节,然后通过 LC-MS 和 HPLC 分析进行探讨。此外,作为初步研究,水溶性单磷酸盐前药4针对MCF-7异种移植裸鼠模型进行了抗肿瘤活性测试。
查看更多